IAS Conference Review 2013

In this review:

Reduced-dose efavirenz non-inferior for efficacy
Overall efficacy of first-line ART
Poor outcomes with suboptimal adherence to HIV therapy
Less bone loss with second-line raltegravir vs NRTIs
Second-line therapy for resource-poor settings
Dolutegravir vs raltegravir in ART-experienced patients
PK and safety of GSK1265744 and TMC278-LA
Tenofovir lowers HIV risk in IV drug users
Genotyping reduces risk of nevirapine skin rash
HIV infection linked to hip fracture

Please login below to download this issue (PDF)

Subscribe